|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADAM8 |
Gene summary for ADAM8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADAM8 | Gene ID | 101 |
| Gene name | ADAM metallopeptidase domain 8 | |
| Gene Alias | CD156 | |
| Cytomap | 10q26.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P78325 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101 | ADAM8 | P2T-E | Human | Esophagus | ESCC | 2.62e-04 | 1.44e-01 | 0.1177 |
| 101 | ADAM8 | P8T-E | Human | Esophagus | ESCC | 2.11e-03 | 1.57e-01 | 0.0889 |
| 101 | ADAM8 | P21T-E | Human | Esophagus | ESCC | 2.20e-04 | 1.50e-01 | 0.1617 |
| 101 | ADAM8 | P37T-E | Human | Esophagus | ESCC | 2.20e-02 | 1.33e-01 | 0.1371 |
| 101 | ADAM8 | P52T-E | Human | Esophagus | ESCC | 2.92e-02 | 1.24e-01 | 0.1555 |
| 101 | ADAM8 | P62T-E | Human | Esophagus | ESCC | 1.87e-05 | 2.35e-01 | 0.1302 |
| 101 | ADAM8 | P65T-E | Human | Esophagus | ESCC | 2.80e-02 | 1.10e-01 | 0.0978 |
| 101 | ADAM8 | P75T-E | Human | Esophagus | ESCC | 2.70e-09 | 1.96e-01 | 0.1125 |
| 101 | ADAM8 | P76T-E | Human | Esophagus | ESCC | 1.34e-11 | 1.86e-01 | 0.1207 |
| 101 | ADAM8 | P82T-E | Human | Esophagus | ESCC | 6.99e-05 | 3.37e-01 | 0.1072 |
| 101 | ADAM8 | P89T-E | Human | Esophagus | ESCC | 4.31e-04 | 7.74e-01 | 0.1752 |
| 101 | ADAM8 | P91T-E | Human | Esophagus | ESCC | 5.86e-08 | 1.03e+00 | 0.1828 |
| 101 | ADAM8 | P126T-E | Human | Esophagus | ESCC | 3.09e-02 | 4.91e-01 | 0.1125 |
| 101 | ADAM8 | P130T-E | Human | Esophagus | ESCC | 3.08e-28 | 6.12e-01 | 0.1676 |
| 101 | ADAM8 | C04 | Human | Oral cavity | OSCC | 2.16e-05 | 3.87e-01 | 0.2633 |
| 101 | ADAM8 | C21 | Human | Oral cavity | OSCC | 1.09e-30 | 1.21e+00 | 0.2678 |
| 101 | ADAM8 | C30 | Human | Oral cavity | OSCC | 1.39e-10 | 6.27e-01 | 0.3055 |
| 101 | ADAM8 | C38 | Human | Oral cavity | OSCC | 9.97e-03 | 2.88e-01 | 0.172 |
| 101 | ADAM8 | C43 | Human | Oral cavity | OSCC | 1.30e-20 | 4.56e-01 | 0.1704 |
| 101 | ADAM8 | C46 | Human | Oral cavity | OSCC | 1.37e-18 | 4.28e-01 | 0.1673 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:0045732111 | Esophagus | ESCC | positive regulation of protein catabolic process | 167/8552 | 231/18723 | 1.47e-16 | 1.14e-14 | 167 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
| GO:0001666111 | Esophagus | ESCC | response to hypoxia | 192/8552 | 307/18723 | 1.59e-09 | 3.69e-08 | 192 |
| GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:0071453110 | Esophagus | ESCC | cellular response to oxygen levels | 114/8552 | 177/18723 | 3.63e-07 | 5.06e-06 | 114 |
| GO:0036294110 | Esophagus | ESCC | cellular response to decreased oxygen levels | 105/8552 | 161/18723 | 4.20e-07 | 5.73e-06 | 105 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADAM8 | SNV | Missense_Mutation | novel | c.1003N>C | p.Glu335Gln | p.E335Q | P78325 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| ADAM8 | SNV | Missense_Mutation | rs761100437 | c.1441N>A | p.Gly481Ser | p.G481S | P78325 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| ADAM8 | SNV | Missense_Mutation | rs764039221 | c.2051G>A | p.Arg684His | p.R684H | P78325 | protein_coding | tolerated(0.2) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ADAM8 | SNV | Missense_Mutation | rs375767499 | c.1910C>T | p.Pro637Leu | p.P637L | P78325 | protein_coding | deleterious(0.01) | benign(0.329) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| ADAM8 | SNV | Missense_Mutation | novel | c.650N>A | p.Gly217Glu | p.G217E | P78325 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ADAM8 | SNV | Missense_Mutation | novel | c.235N>G | p.Leu79Val | p.L79V | P78325 | protein_coding | tolerated(0.43) | benign(0.075) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ADAM8 | SNV | Missense_Mutation | novel | c.242N>T | p.Ser81Phe | p.S81F | P78325 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ADAM8 | SNV | Missense_Mutation | novel | c.2048N>A | p.Ser683Asn | p.S683N | P78325 | protein_coding | tolerated(0.42) | benign(0.011) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ADAM8 | SNV | Missense_Mutation | novel | c.1424T>C | p.Leu475Pro | p.L475P | P78325 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ADAM8 | SNV | Missense_Mutation | novel | c.2402N>T | p.Ala801Val | p.A801V | P78325 | protein_coding | tolerated(0.3) | benign(0.046) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 101 | ADAM8 | ENZYME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166879 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |